Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases

World Journal of Surgical Oncology

Research

Evangelos Briasoulis¹  Nikoforos Apostolikas²  Anna Batistatou³  Ioannis Panelos³  Dimitrios Stefanou³  Emilios Pakos⁴  Pinelopi Gogou⁴  Periclis Tsekeris⁵ 

[1] Cancer Biobank Center, University of Ioannina, P.O. Box 1186, University Campus, 45110, Ioannina, Greece;Department of Pathology, St Savvas Cancer Hospital, Athens, Greece;Department of Pathology, University of Ioannina, Medical School, Ioannina, Greece, Stavrou Niarhou Av 1., 45500, Ioannina, Greece;Department of Radiation Oncology, University Ioannina, Medical School, Stavrou Niarhou Av 1., 45500, Ioannina, Greece;Department of Radiation Oncology, University Ioannina, Medical School, Stavrou Niarhou Av 1., 45500, Ioannina, Greece;Cancer Biobank Center, University of Ioannina, P.O. Box 1186, University Campus, 45110, Ioannina, Greece;

关键词: liposarcomas;    E-cadherin;    b-catenin;    topoisomerase II alpha;    prognosis;   

DOI  :  10.1186/1477-7819-10-28

 received in 2011-05-10, accepted in 2012-02-02,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundTo investigate the expression of E-cadherin, beta-catenin and topoisomerase-II alpha and examine their clinical relevance in liposarcomas.Materials and methodsThe expression of E-cadherin, beta-catenin and topoisomerase II alpha was examined immunohistochemically on formalin-fixed paraffin-embedded tissue specimens from 71 patients who underwent surgical treatment for liposarcomas of the extremities or the retroperitoneum in two major cancer reference centres between 1990 and 2000. Detailed medical notes were available for all patients who were followed for median 82 months (range 5 to 215 months). Obtained expression data were weighted against clinical and pathology parameters of clinical relevance.ResultsPatients were mostly male (59%), median age was 56 years for the liposarcomas of the extremities and 60 years for the retroperitoneal liposarcomas. The tumours were of diverse histology, grade and size (median diameters 7 and 17 cm for tumours of the extremities and retroperitoneum respectively). Expression of β-catenin protein was weakly detected in 15 cases (21.1%). Similarly weak expression of topoisomerase II-alpha was detected in 14 (19.7%) cases of which only two had more than 20% of tumor cells stained positive. E-cadherin was not detected in the studied cohort of liposarcomas. We did not detect associations between the expression of the above proteins by liposarcoma cells and clinical outcome.ConclusionsLiposarcomas do not express E-cadherin, which matches the absence of epithelioid differentiation in this sarcoma subtype, and have low topoisomerase II-alpha expression, which justifies to some extend their resistance to anthracycline-based chemotherapy.

【 授权许可】

Unknown   
© Gogou et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.